eTheRNA Archives

Optics11 Life receives €5 million in funding for drug development

News and Trends 24 Aug 2022

Millions in funding and new board members for Belgian mRNA company

The mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in series B2 financing. Belgium-based eTheRNA will use the money to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy. The round was led by Novalis LifeSciences LLC with participation from Professor Kenneth Chien, […]

August 24, 2022 - 3 minutesmins - By Liza Laws

In Depth 28 Jul 2022

How can vaccines keep up with evolving Covid-19 variants?

Vaccines for COVID-19 have saved lives all over the world, but their protection is threatened by the rise of variants of concern. Companies are developing ways to combat the evolving virus, such as booster shots and universal coronavirus vaccines. During 2021, a plethora of COVID-19 vaccines was rolled out around the world. Since then, mass […]

July 28, 2022 - 7 minutesmins - By Jonathan Smith

covid 19 vaccine patent waiver intellectual property ip

News and Trends 15 Jun 2021

Patent Waiver on Covid-19 Vaccines Splits Opinions in Biotech Industry

Attempts to increase global Covid-19 vaccine coverage with a temporary patent waiver have been met with hostility from many big pharma and biotech companies, but some smaller players welcome the idea. With the Covid-19 pandemic still rampaging through many countries and new viral variants popping up with alarming regularity, scuffles over who holds intellectual property […]

June 15, 2021 - 5 minutesmins - By Anita Chakraverty

News and Trends 18 Jun 2020

Belgian mRNA Vaccine for Covid-19 Receives €34M Series B Boost

Belgian biotech eTheRNA has secured €34M in Series B funding to progress to the clinic its Covid-19 vaccine candidate and cancer immunotherapies made from messenger RNA. The company’s five existing investors contributed to the round, including Dutch VC firm LSP, and the Boehringer Ingelheim Venture Fund, based in Germany. Four new investors also contributed — […]

June 18, 2020 - 3 minutesmins - By Helen Albert

In Depth 30 Mar 2020

Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?

The first vaccine against coronavirus disease could one day be made of mRNA. How is mRNA showing promise against the pandemic, and what could it signify for the mRNA field? The global number of coronavirus disease (Covid-19) cases has passed 600,000 and is threatening to bring healthcare systems worldwide to their knees. To control the […]

March 30, 2020 - 7 minutesmins - By Jonathan Smith

News and Trends 11 Dec 2018

What Does the Largest Biotech IPO Ever Mean for European Biotech?

With a massive €530M ($604M) raised, US-based Moderna has made a record biotech IPO. The news could give a significant boost to developers of messenger RNA, a technology that is still several years away from the market. Entering the Nasdaq with a €7B ($8B) market cap, Moderna made history last Friday with a technology that […]

December 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jun 2017

Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma

eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy based on off-the-shelf mRNA technology. eTheRNA is one of the few companies working in mRNA therapies that are running clinical trials. The Belgian biotech has announced the start of a Phase Ib trial with its candidate TriMix-MEL, also called ECI-006, in patients […]

June 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 26 Apr 2017

Infographic: Who’s who in the mRNA Therapeutics Field in Europe?

The young field of mRNA therapeutics is booming and generating huge expectations. Which are the main players in Europe turning them into a reality? Therapies based on mRNA promise better vaccines and therapeutics by instructing the body to produce its own just by reading the instructions written in the RNA sequence. Thought for a long time to […]

April 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

eTheRNA

Millions in funding and new board members for Belgian mRNA company

How can vaccines keep up with evolving Covid-19 variants?

Patent Waiver on Covid-19 Vaccines Splits Opinions in Biotech Industry

Belgian mRNA Vaccine for Covid-19 Receives €34M Series B Boost

Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?

What Does the Largest Biotech IPO Ever Mean for European Biotech?

Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma

Infographic: Who’s who in the mRNA Therapeutics Field in Europe?

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!